<DOC>
	<DOCNO>NCT01526837</DOCNO>
	<brief_summary>This phase 1b study safety tolerability bevacizumab ( Avastin ) administer tumor resection cavity subject Glioblastoma Multiforme ( GBM ) first recurrence .</brief_summary>
	<brief_title>Bevacizumab ( Avastin ) Into Tumor Resection Cavity Subjects With Glioblastoma Multiforme First Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Recurrent Glioblastoma 2 . At least 12 week expect survival ( KPS &gt; 60 ) 3 . 18 year age old 4 . Able willing participate 1 . Any prior diagnosis cancer concurrent malignancy . 2 . Planned use current use investigation therapy . 3 . Systemic autoimmune disease 4 . HIV positive 5 . Concurrent life threaten disease 6 . Impaired organ function 7 . Active infection 8 . Inadequately controlled hypertension 9 . Congestive heart failure 10 . Myocardial infection/unstable angina within 6 month 11 . Stroke within 6 month 12 . Pheripheral vascular disease 13 . History abdominal fistula/gastrointestinal performation 14 . Nonhealing wound 15 . Coagulation disease 16 . Known allergy study treatment 17 . Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>GBM</keyword>
	<keyword>Brain cancer</keyword>
</DOC>